Kopran Ltd (KOPRAN)

📊 Quarterly Results (₹ Cr)

Kopran's financial trajectory shows a clear inflection point after a loss in September 2025 (₹-10 crore NP), with profitability recovering in December 2025 (₹9 crore NP) and accelerating in Q1 FY2026 (₹7 crore consolidated profit). Operating performance improved sequentially, with OPM expanding from 6.5% in June 2026 to 12.2% in March 2026, indicating margin recovery despite revenue volatility. While revenue dipped from ₹234 lakhs in March to ₹154 lakhs in June 2026, profitability remained stable, suggesting cost discipline or product mix improvement. The company has not disclosed revenue figures in filings but consistently cites export growth and API demand as drivers, aligning with the upward trend in margins and net income.

🔮 Management Outlook & What's Next

Management's forward-looking statements, as referenced in the August 7, 2026 financial results filing, emphasize continued investment in R&D for niche APIs, capacity expansion, regulatory compliance, and reducing dependence on China. These priorities were reiterated during the board meeting where Q1 FY2026 results were approved, signaling a sustained focus on strategic technical and operational development. No formal long-term guidance was provided, but the appointment of a seasoned CTO and ongoing board-level discussions around growth execution suggest a structured, phased approach to scaling operations in high-value therapeutic segments.

Extracted from official company announcements. Not StockFin.ai's opinion.

🏦 Balance Sheet (₹ Cr)

The balance sheet reflects a stable and conservative capital structure, with total assets growing from ₹813 lakhs in March 2025 to ₹908 lakhs in March 2026, driven by asset accumulation despite flat equity. Borrowings have slightly increased from ₹148 to ₹157 lakhs, indicating modest leverage expansion, likely to fund working capital or growth initiatives. Equity remains constant at ₹48 lakhs, but reserves have grown from ₹470 to ₹482 lakhs, suggesting retained earnings are being built. The company is not pursuing aggressive debt financing, instead relying on internal cash flows and selective capital deployment, consistent with its focus on operational stability and regulatory self-reliance.

💰 Cash Flow Statement (₹ Cr)

👥 Shareholding Pattern

Promoter holding remains stable at 44.42% across all recent quarters, indicating confidence from the founding group. Institutional investor interest is minimal, with FII ownership fluctuating slightly between 0.36% and 0.60% over the past year, and DII holding at 0%. The number of public shareholders has increased from 56,925 to 62,222, suggesting retail investor engagement is growing. There are no signs of promoter selling or significant institutional accumulation, but the broadening shareholder base may improve liquidity. No pledging activity is disclosed, and the upcoming dividend announcement, contingent on AGM approval, may attract short-term interest.

⚖️ Peer Comparison — Pharmaceuticals

🔗 Peer Stock Analyses

⚠️ Risk Factors

1. Execution risk in growth initiatives: Management's focus on R&D and capacity expansion must deliver commercial results, but current revenue trends show volatility, raising concerns about scalability. 2. Margin sensitivity: Despite OPM improvement, profitability remains fragile, as seen in the swing from ₹-10 crore to ₹7 crore profit in consecutive quarters, indicating exposure to input costs or pricing pressures. 3. Regulatory and China dependency risk: While management cites efforts to reduce reliance on China, the extent and timeline of this transition are unclear and could impact supply chain stability. 4. Low institutional visibility: Minimal FII/DII participation may limit trading interest and make the stock vulnerable to promoter-driven or retail volatility.

📋 Recent Filings

• Announcement2026-09-25Kopran Ltd announced that its trading window will close on October 1, 2026, for insiders until 48 hours after the unaudited Q2 results are declared, w…
• 🔴 Announcement2026-09-22Kopran Ltd clarified that its share price movement is purely market-driven with no undisclosed material events, reaffirming compliance with SEBI Regul…
• 🔴 Corporate Action2026-09-16Kopran Ltd announced the allotment of 40,500 equity shares to eligible employees under its 2023 ESOP, increasing paid-up capital from Rs. 482.85605 cr…
• Announcement2026-09-01Kopran Ltd clarified that a recent spike in trading volume is purely market-driven and not linked to any undisclosed material event, reaffirming compl…
• 🔴 Financial Results2026-08-07Kopran Limited reported Q1 FY2026-27 revenue of [amount not verified], up sharply from [amount not verified] in Q1 FY2025-26, driven by strong API and…
• 🟡 Board Meeting2026-08-07Kopran Limited announced the outcome of its board meeting held on August 7, 2026, where it approved the unaudited standalone and consolidated financia…
• 🔴 Corporate Action2026-07-16Kopran Limited announced that the record date for dividend payment, contingent on shareholder approval at the August 18, 2026 AGM, is set for August 1…
• share transfer2026-07-09Kopran Limited received a SEBI-registered share transfer agent certificate confirming compliance with Regulation 74(5) for the quarter ended June 30, …
• 🔴 Announcement2026-06-26Kopran Limited announced the appointment of Vijay L Thange as Chief Technical Officer effective June 26, 2026, adding deep pharma operations expertise…
• Financial Results2026-06-24Kopran Limited announced that its trading window will close on July 1, 2026, for directors and designated persons until 48 hours after the unaudited Q…

🧠 Analyst's Read

Kopran Ltd is transitioning from operational instability to a phase of strategic investment in niche API capabilities and regulatory self-reliance, supported by improving profitability and leadership upgrades. The company's financial trajectory shows signs of stabilization, but growth execution and margin sustainability remain key watchpoints. Investors should monitor the outcome of the upcoming AGM for dividend approval and the pace of R&D commercialization, as these will determine the trajectory of its long-term value creation narrative.

Based on filing content and financial data. Not a recommendation.